Dalcetrapib a Potential Game Changer for Cholesterol Management

Dalcetrapib a Potential Game Changer for Cholesterol Management

dalcetrapib jtt 705Dalcetrapib JTT-705 CAS# 211513-37-0, is in experimental stages and clinical development for prevention of cardiovascular events. Developed by Roche to increase good cholesterol, or HDL, in patients, dalcetrapib has proved efficacy in studies thus far. Positive results from clinical trials have also shown no increase in blood pressure in patients studied.

Data released from a research trial showed that after 36 weeks dalcetrapib had increased high-density cholesterol (HDL) levels by an average of 31 % in 476 patients studied. Deemed dal-VESSEL, this study was a phase IIB, randomized, double-blind, placebo-controlled study. Participants in this study received either a 600 milligram dose of dalcetrapib or a placebo. The safety and efficacy of dalcetrapib in this study was apparent. Researchers from Roche were pleased to point out that of the 476 patients in the study, there were no patients that demonstrated catastrophic cardiac risks, unlike Pfizer’s torcetrapib did over five years ago. Another study, involving 130 patients, named dal-PLAQUE, was also reported successful. In this study the primary objective was to assess the effect of dalcetrapib on atherosclerotic plaque inflammation in patients after six months of use. The dosage was 600 milligrams once daily for trial participants.


New approaches to CETP modulation dal-HEART Program


A Phase III study, dal-ACUTE, is the fifth study in the dal-HEART Program. This study will evaluate the efficacy and safety of dalcetrapib in approximately 300 patients. The patient profile for this study involves participants who experienced acute coronary syndrome, and are receiving treatment soon after the event via dalcetrapib. This study is due to last  20 weeks, and dose patients at 600 milligrams once daily.

As a modulator of cholesteryl ester transfer protein (CETP), dalcetrapib has been shown to be effective in controlling side effects such as flushing. Dalcetrapib also does not appear to show a risk of increasing blood glucose levels, which will significantly widen the appeal for both the prescriber and patient, once it is approved.

LGM Pharma is a provider of the API dalcetrapib for research and development, and offers assistance to clients through all stages of research.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:
This website uses cookies. By using our site, you agree to our terms of service